Proximagen's vision is to become one of the world's leading companies developing therapeutics for patients suffering from diseases of the CNS.
Proximagen's team of scientists is continually working to identify new opportunities
to meet the health care challenges of patients with diseases of the central nervous
system. Built on over 25 years of leadership in neurodegenerative research, Proximagen
utilises this experience and aims to bring the best research and development programmes
to commercialisation.
Proximagen views external collaborations and partnerships as a fundamental part of
its business, and the company is always looking to evaluate exciting opportunities. Proximagen
partners with universities and companies to find, develop and commercialise products
that aim to improve the lives of patients.
Please visit the our resource library to learn about recent Proximagen publications.
